Clinical Outcomes
Continuous glucose monitoring (CGM) can be useful for many different patient populations. Proper patient selection is essential to successful use of CGM in a practice setting.
Overview
Studies reveal Continuous Glucose Monitoring increases glycemic awareness, reduces A1C levels, and improves long-term health.
Better Detection of Dangerous Glucose Variability
- Detects 4 times as many dangerous highs and lows than fingersticks alone*1
- 60% of lows may not be revealed by fingerstick testing1
- People with diabetes only use fingersticks an average of 4 to 5 times per day
- A1C testing provides a 2 to 3 month average of glucose levels, but isn’t intended to track highs and lows2
- Prevents or reduces the duration of hypoglycemic episodes
Improves Diabetes Management
- In a pilot study (n=16) people with diabetes using Guardian continuous glucose monitoring reported:3
- 94% used readings and/or alerts to control their glucose levels
- 81% had greater satisfaction with their glucose control
- 75% adjusted their insulin delivery
- 63% changed their diet
- 31% made lifestyle changes
- Utility and accuracy supported by over 200 clinical publications
Blinded CGM Study Results
- 85% (N=322) had distinctive "peaks" and "drop-offs" subject to considerable variability4
- Use of CGM is a minimally invasive method of determining individual basal rates vs BG meter testing4
- Significantly shorter duration of hypoglycemia than the BG group, overnight and overall5
- Significantly reduced A1C from 8.7 ±1.6% to 8.3 ±1.3% from 3 months before CGM to 6 months after1
Read about the Medtronic continuous glucose monitoring solutions.
Contraindications
Successful operation of CGM device requires adequate vision and hearing. Use of a continuous glucose monitoring system is not recommended for patients whose impaired vision or hearing does not allow full recognition of the monitor signals and alarms, or who do not have a caregiver that can perform this function for them.
Warnings/Precautions
Continuous glucose monitor users should be educated to program and operate the monitor and respond to alarm conditions prior to attempted use of the system.
The current and voltage signals shown in the monitor are to be used only for finding potential problems with the Continuous Glucose Monitoring System and do not indicate current glucose value. Infection and/or site irritation may result from improper insertion and maintenance of insertion site.
Safety Information
Patients should always discuss potential risks and benefits with a physician. Please review the product manual prior to use for detailed instructions and disclosure.
For complete safety information, including contraindications, warnings/complications, and potential complications, see product label or visit the Indications, Safety, and Warnings page.
* A confirmatory fingerstick test is required prior to taking action.
References
- Kaufman FR, Gibson LC, Halvorson M, et al. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24(12):2030-2034.
- Derr R, Garrett E, Stacy G, et al. Is HbA1C affected by glycemic instability? Diabetes Care. 2003;26(10):2728-2733.
- Deiss D, et al. Diabetes. 2005;54(suppl 1):393-P.
- Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005;69(1):14-21.
- Tanenberg R, Bode B, Lane W, et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521-1526.
